[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-342293-105":59,"doc-detail-342293-en":130},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":123,"head_meta":125,"extra_data":127,"updated_unix":129},105,"en","innovative-therapies-targeting-drug-resistant-biomarkers-in-metastatic-clear-cell-renal-cell-carcinoma-ccrcc","Innovative Therapies Targeting Drug-Resistant Biomarkers in Metastatic Clear Cell Renal Cell Carcinoma (ccRCC)","","A thorough study of Clear Cell Renal Cell Carcinoma (ccRCC) evaluates how combining tyrosine kinase inhibitors with immune checkpoint inhibitors addresses tumor-promoting effects driven by abnormal immunological and molecular biomarkers. These biomarkers are linked to enhanced drug resistance, tumor growth, and cancer-related gene activation. The work surveys ongoing clinical trials exploring newer options with potentially improved efficacy, while emphasizing the need for further research to verify long-term safety, toxicity, and side effects. It summarizes key biomarkers and drug candidates associated with survival benefits.",{"@graph":69,"@context":122},[70,84,105],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/innovative-therapies-targeting-drug-resistant-biomarkers-in-metastatic-clear-cell-renal-cell-carcinoma-ccrcc/342293/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/innovative-therapies-targeting-drug-resistant-biomarkers-in-metastatic-clear-cell-renal-cell-carcinoma-ccrcc/342293.png","ImageObject",300,407,{"name":92,"@type":93},"Aurelia","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-11-08","2026-09-22",true,{"@type":102,"interactionType":103,"userInteractionCount":29},"InteractionCounter",{"@type":104},"ViewAction",{"@type":106,"mainEntity":107},"FAQPage",[108,114,118],{"name":109,"@type":110,"acceptedAnswer":111},"Why are drug-resistant biomarkers important in metastatic ccRCC?","Question",{"text":112,"@type":113},"The study links abnormal biomarkers to increased drug resistance, tumor growth, and activation of cancer-related genes in metastatic ccRCC.","Answer",{"name":115,"@type":110,"acceptedAnswer":116},"What combination therapy approach is highlighted in the research?",{"text":117,"@type":113},"Combining tyrosine kinase inhibitors (TKIs) with immune checkpoint inhibitors (ICIs) is presented as showing promising results for metastatic ccRCC.",{"name":119,"@type":110,"acceptedAnswer":120},"What evidence gaps does the article emphasize?",{"text":121,"@type":113},"It calls for more research to confirm long-term safety, appropriate use over time, and potential side effects of the emerging treatment options.","https://schema.org",{"og:url":83,"og:type":124,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":126,"canonical":83},"index,follow",{"doc_id":128,"site_id":62},342293,1792220205,{"code":4,"msg":5,"data":131},{"doc_id":128,"user_id":132,"nickname":92,"user_avatar":133,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":29,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":46,"language":139,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":140,"faqs":141,"seo_title":142,"seo_description":67,"update_tm":143,"read_time":31,"preview_page_count":19,"preview_urls":144},1099514068365,"https://ap-avatar.wpscdn.com/avatar/10000253d8d9f28188e?x-image-process=image/resize,m_fixed,w_180,h_180&k=1794309523707217728","Review  \nInnovative Therapies Targeting Drug-Resistant Biomarkers in Metastatic Clear Cell Renal Cell Carcinoma (ccRCC)  \nMoses Owoicho Abah 1,2, *, Deborah Oganya Ogenyi 1, Angelina V. Zhilenkova 1, Freddy Elad Essogmo 1, Yvan Sinclair Ngaha Tchawe 1, Ikenna Kingsley Uchendu 1,3, Akaye Madu Pascal 1, Natalia M. Nikitina 1, Alexander S. Rusanov 1, Varvara D. Sanikovich 1, Yuliya N. Pirogova 1, Alexander Boroda 1, Aleksandra V. Moiseeva 1 and Marina I. Sekacheva 1  \nAcademic Editor: Nobuya Sasaki  \nReceived: 14 November 2024  \nRevised: 9 December 2024  \nAccepted: 14 December 2024  \nPublished: 31 December 2024  \nCitation: Abah, M.O.; Ogenyi, D.O.; Zhilenkova, A.V.; Essogmo, F.E.; Ngaha Tchawe, Y.S.; Uchendu, I.K.; Pascal, A.M.; Nikitina, N.M.; Rusanov, A.S.; Sanikovich, V.D.; et al. Innovative Therapies Targeting Drug-Resistant Biomarkers in Metastatic Clear Cell Renal Cell Carcinoma (ccRCC) . Int. J. Mol. Sci. 2025, 26, 265. [https://](https://)[ ](https://)[doi.org/10.3390/ijms26010265](doi.org/10.3390/ijms26010265)  \n[Copyright:](Copyright:) © 2024 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license ([https://creativecommons.org/](https://creativecommons.org/)[ ](https://creativecommons.org/)[licenses/by/4.0/](licenses/by/4.0/)) .  \n1 World-Class Research Center “Digital Biodesign and Personalized Healthcare”, Sechenov First Moscow State Medical University, Moscow 119991, Russia; [ogenyideborah@gmail.com](ogenyideborah@gmail.com) (D.O.O.);  \n[av.zhilenkova@gmail.com](av.zhilenkova@gmail.com) (A.V.Z.); [essogmo_f@student.sechenov.ru](essogmo_f@student.sechenov.ru) (F.E.E.);  \n[ngakhatchave_i@student.sechenov.ru](ngakhatchave_i@student.sechenov.ru) (Y.S.N.T.); [akayepaschal48@gmail.com](akayepaschal48@gmail.com) (A.M.P.);  \n[nikitinanm@gmail.com](nikitinanm@gmail.com) (N.M.N.); alexrus146@yandex.ru (A.S.R.); [v8varvara@gmail.com](v8varvara@gmail.com) (V.D.S.);  \n[pirogova_yuliya96@mail.ru](pirogova_yuliya96@mail.ru) (Y.N.P.); [alexcom90@yandex.ru](alexcom90@yandex.ru) (A.B.);  \n[moiseeva_a_v@student.sechenov.ru](moiseeva_a_v@student.sechenov.ru) (A.V.M.); [sekach_rab@mail.ru](sekach_rab@mail.ru) (M.I.S.)  \n2 Department of Cancer Bioinformatics and Molecular Biology, Royal Society of Clinical and Academic Researchers (ROSCAR) International, Abuja 900104, Nigeria  \n3 Medical Laboratory Science Department, Faculty of Health Science and Technology, College of Medicine, University of Nigeria, Enugu Campus, Enugu 410001, Nigeria  \n* Correspondence: [abahmoses28@gmail.com](abahmoses28@gmail.com)  \nAbstract: A thorough study of Clear Cell Renal Cell Carcinoma (ccRCC) shows that combining tyrosine kinase inhibitors (TKI) with immune checkpoint inhibitors (ICI) shows promising results in addressing the tumor-promoting influences of abnormal immunological and molecular biomarkers in metastatic Clear Cell Renal Cell Carcinoma (ccRCC) . These abnormal biomarkers enhance drug resistance, support tumor growth, and trigger cancerrelated genes. Ongoing clinical trials are testing new treatment options that appear more effective than earlier ones. However, more research is needed to confirm their long-term safety use and potential side effects. This study highlights vital molecular and immunological biomarkers associated with drug resistance in Clear Cell Renal Cell Carcinoma (ccRCC) . Furthermore, this study identifies a number of promising drug candidates and biomarkers that serve as significant contributors to the enhancement of the overall survival of ccRCC patients. Consequently, this article offers pertinent insights on both recently completed and ongoing clinical trials, recommending further toxicity study for the prolonged use of this treatment strategy for patients with metastatic ccRCC, while equipping researchers withinvaluable information for the progression of current treatment strategies.  \nKeywords: ","cbCaipsvXDncgjzW","https://ap.wps.com/l/cbCaipsvXDncgjzW","pdf",1301984,"English","# Introduction","[{\"question\":\"Why are drug-resistant biomarkers important in metastatic ccRCC?\",\"answer\":\"The study links abnormal biomarkers to increased drug resistance, tumor growth, and activation of cancer-related genes in metastatic ccRCC.\"},{\"question\":\"What combination therapy approach is highlighted in the research?\",\"answer\":\"Combining tyrosine kinase inhibitors (TKIs) with immune checkpoint inhibitors (ICIs) is presented as showing promising results for metastatic ccRCC.\"},{\"question\":\"What evidence gaps does the article emphasize?\",\"answer\":\"It calls for more research to confirm long-term safety, appropriate use over time, and potential side effects of the emerging treatment options.\"}]","Innovative Therapies Targeting Drug-Resistant Biomarkers in Metastatic Clear Cell Renal Cell Carcinoma (ccRCC) | PDF",1790046040,[145,149,153,157],{"page_no":8,"url":146,"width":147,"height":148},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/3c8fba4898b34119a6744e3343da2411.webp",983,1390,{"page_no":14,"url":150,"width":151,"height":152},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/ca7a2ff84bf6c947fe89527652770962.webp",982,1388,{"page_no":81,"url":154,"width":155,"height":156},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/0c0f90b605d518d4dada6816468a6191.webp",981,1387,{"page_no":19,"url":158,"width":159,"height":160},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/44b563349132e3866fabd1510312dc63.webp",980,1385]